Review Article

Long-term Safety of Oral Anti-viral Treatment for Chronic Hepatitis B

G. L.-H. Wong; W.-K. Seto; V. W.-S. Wong; M.-F. Yuen; H. L.-Y. Chan


Aliment Pharmacol Ther. 2018;47(6):730-737. 

In This Article


With more data from real-life cohorts of sufficiently large sample size and long follow-up durations, the long-term safety profile of NAs is now more clearly defined. Together with a new nucleotide analogue, TAF, with further improvement in renal and bone safety profile, CHB patients receiving NA treatment for years and even decades can be reassured that this treatment would bring them clinically beneficial effects with minimal side effects. This would be one of the key elements to ensure drug adherence in our CHB patients.